HSCT

·One of the most active bone marrow transplant centres in the world

·World leader in haplo bone marrow transplantation·Excellent results in the treatment of refractory relapsed blood disorders

·Since 2014, the number of non-blood transplants at Lu Daopei Hospital has been the highest in China

Total Number of HSCT 

(reference: https://bethematch.org/tcdirectory/search/advanced/）

Number oftransplantsperyear

Lu Dao Pei Hospital leads the world in allogeneic haematopoietic stem cell transplants

resource：NMDPhttps://bethematch.org/tcdirectory/search/advanced/

Trends in the age group composition of patients per year

HCT with related HLA-mismatched donors is a feasible approach with acceptable outcomes and can achieve comparable results to HLA-identical sibling transplantation.

Haplo-HSCT vs. Sibling HSCT

The cumulative incidence of II-IV aGVHD was 32% in the matched group and 40% in the mismatched group. 

The incidence of cGVHD was not significantly different between the two groups.

(aGVHD: Acute Graft-versus-Host Disease

cGVHD: Chronic Graft-versus-HostDisease)

Two-year adjusted LFS and OS were 71% and 72% in the matched group and 64% and 71% in the mismatched group, respectively. 

LFS and OS were not significantly different between the two groups.

(LFS: leukaemia-free survival

OS: overall survival)

Haplo-HSCT in AML

The LFS of HSCT for AML was 76.9% in CR1, 74.1% in CR2 and 48.2% in NR.

(AML: Acute myeloid leukaemia

CR1: First complete remission

CR2: Second complete remission

NR: No remission)

Haplo-HSCT in ALL

The LFS of HSCT for ALL is 78.9% in CR1, 56.6% in CR2 and 38.0% in NR.

(ALL: Acute lymphoblastic leukaemia)

Allo-HSCT in MDS

There was no significant difference in OS rate between MDS patients who received unrelated, sibling and haploidentical transplants.

(MDS: Myelodysplastic syndrome)

Patient age at haplo-HSCT

There was no significant difference in OS rate between MDS patients who received unrelated, sibling and haploidentical transplants.

Result of HSCT (2019)

- Allo-HSCT: 1078/1081 (99.7%) (Allogeneic HSCT: Allogeneic HSCT)

- TRM of day 100: 88/1081 (8.1%) (TRM: Treatment-related mortality)

The Records

The first BMT in Asia in 1964 and the longest survivor:

Due to severe aplastic anaemia (SAA), the patient received syn -BMT from Dr Lu, Daopei in 1964. She is still alive and healthy today. It is the first HSCT in Asia, also the fourth BMT patient in the world and the longest disease-free survival after BMT in the world.

(syn: syngeneic)

The youngest patient (2.5 months old): 

The patient, born at two months due to congenital immunodeficiency disease, had undergone unrelated double cord blood transplantation at Lu Daopei Hospital. The haematopoietic and immune functions had returned to normal after the transplant.

The oldest for URD-HSCT (65 years): 

A 65-year-old patient with ALL received a haematopoietic stem cell transplant. He returned to a normal life after the transplant.

(URD: Unrelated donor)

The heaviest (95kg) for a (double) cord blood transplant: 

ALL with central nervous system leukaemia, the first patient to receive a double cord blood transplant. He was healthy after the transplant and had returned to work for 14 years.